.Nature Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ innovative breast cancer cells as well as energetic or even secure brain metastases showed consistent intracranial task as well as systemic efficiency of T-DXd.